

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
192nd Meeting of the
Vaccines and Related Biological Products Advisory Committee
May 28, 2026
Draft AGENDA**

Topic: The committee will meet in open session to discuss and make recommendations on the selection of the 2026-2027 Formula for COVID-19 vaccines for use in the United States.

EST Time	Presentation/Presenter
8:30 am – 8:50 am	<p><u>Opening Remarks: Call to Order and Welcome</u> (10 min)</p> <p>Stanley Perlman, MD, PhD, Acting Chair, VRBPAC</p> <p><u>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement</u> (10 min)</p> <p>LCDR Cicely C. Reese, PharmD Designated Federal Officer (DFO), VRBPAC Center for Biologics Evaluation and Research (CBER), FDA</p>
8:50 am – 9:05 am	<p><u>Introduction</u> (15 min Total Including Q/A)</p> <p>Jerry Weir, PhD (10 min) Director, Division of Viral Products (DVP) Office of Vaccines Research and Review (OVRR) CBER, FDA</p> <p>Q/A: 5 min</p>
9:05 am – 10:05 am	<p><u>CDC Presentations</u> (60 min Total Including Q/A)</p> <p>Update on Current Epidemiology of COVID-19 and SARS-CoV-2 Variants (25 min)</p> <p>Natalie J. Thornburg, PhD Chief, Laboratory Branch Coronaviruses and Other Respiratory Viruses Division National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention (CDC)</p> <p>Q/A: 5 Min</p> <p>Updates on COVID-19 Vaccine Effectiveness (25 min)</p> <p>Amanda B Payne, PhD, MPH Acting Team Lead Prevention Effectiveness and Evidence Review Team Surveillance and Prevention Branch CORVD, NCIRD, CDC</p> <p>Q/A: 5 min</p>

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
192nd Meeting of the
Vaccines and Related Biological Products Advisory Committee
May 28, 2026
Draft AGENDA**

10:05 am – 10:40 am	<p><u>TAG-CO-VAC Presentation (35 min Total Including Q/A)</u></p> <p><u>TAG-CO-VAC May 2026 Recommendation on Antigen Composition of COVID-19 Vaccines (25 min)</u></p> <p>Bart Haagmans, PhD Associate professor Department of Viroscience Erasmus MC, Rotterdam, the Netherlands</p> <p>Q/A: 10 min</p>
10:40 am – 11:00 am	Break (20 min)
11:00 am – 11:20 am	<p><u>Moderna Presentation (20 min Total Including Q/A)</u></p> <p>SPIKEVAX and MNEXSPIKE COVID-19 Vaccines Update</p> <p>Darin Edwards, PhD Executive Director COVID-19 Program Lead</p> <p>Rituparna Das, MD, PhD Head of Clinical Development</p>
11:20 am – 11:40 am	<p><u>Pfizer Presentation (20 min Total Including Q/A)</u></p> <p>COMIRNATY COVID-19 Vaccine Update</p> <p>Kayvon Modjarrad, MD, PhD Global Medical Affairs Lead, Vaccines</p>
11:40 am – 12:00 pm	<p><u>Sanofi Presentation (20 min Total Including Q/A)</u></p> <p>NUVAXOVID COVID-19 Vaccine Update</p> <p>Tonya Colpitts, PhD Associate Vice President Global Project Head, Vaccines</p>
12:00 pm – 12:20 pm	<p><u>FDA Presentation (20 min Total Including Q/A)</u></p> <p>FDA Considerations and Recommendation for COVID-19 Vaccine 2026-2027 Formula (20 Min)</p> <p>Carol D. Weiss, MD, PhD Medical Officer Division of Clinical & Toxicology Review Office of Vaccines Research and Review, CBER, FDA</p>

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
192nd Meeting of the
Vaccines and Related Biological Products Advisory Committee
May 28, 2026
Draft AGENDA

12:20 pm – 1:00 pm	Lunch (40 min)
1:00 pm – 2:00 pm	<u>Open Public Hearing</u> (60 min)
2:00 pm – 2:30 pm	<u>Additional Q & A for CDC, FDA, and Industry Presenters</u> (30 min)
2:30 pm – 4:30 pm	<u>Committee Discussion of Vaccine Formula Selection and Voting</u> (up to 120 min)
4:30 p.m.	<u>Closing Remarks and Adjournment</u>